Login to Your Account


Elan Moves ELND005 into Phase III, Nixes Drug Delivery

By Cormac Sheridan


Wednesday, August 11, 2010
DUBLIN, Ireland – Elan Corp. plc has decided against spinning out its drug delivery arm, Elan Drug Technologies (EDT), into a separate business after concluding that "market conditions at this time are not conducive to an appropriate valuation." (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription


»

Our address has changed:
BioWorld | 115 Perimeter Center Place
Suite: 1100 | Atlanta, Georgia 30346, USA
 
For Sales Inquiries:
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
Fax: 1-770-810-3145
BioWorld.salessupport@thomsonreuters.com
 
Privacy Policy | Terms of Use
 
Part of Thomson Reuters
Note: our contact information has changed
Customer Service:
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
bioworld.support@thomsonreuters.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
© 2013 Thomson Reuters. Reproduction, reposting content is strictly prohibited.

Free Ezine

Sign up for Perspectives FREE e-mail newsletter

Click here